# SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

> **NCT05163080** · PHASE2 · UNKNOWN · sponsor: **MimiVax, LLC** · enrollment: 247 (estimated)

## Conditions studied

- Newly Diagnosed Glioblastoma

## Interventions

- **BIOLOGICAL:** SurVaxM

## Key facts

- **NCT ID:** NCT05163080
- **Lead sponsor:** MimiVax, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-18
- **Primary completion:** 2024-08-18
- **Final completion:** 2024-08-18
- **Target enrollment:** 247 (ESTIMATED)
- **Last updated:** 2024-02-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05163080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05163080, "SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05163080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*